MetLife enters the back half of June having quietly outrun most of its life-insurance peers this week, with the stock up 0.7% to $88.03 while the closest comparables PRU and UNM slipped into the red.
The more interesting story this week sits on the analyst desk. The Street has been lifting its view on MetLife in a remarkably consistent direction — virtually every firm that touched the name since early May raised its target rather than cut it. Morgan Stanley maintained Overweight and nudged its target to $93 in late May. JPMorgan held Overweight and moved to $96. Barclays and Wells Fargo both raised targets to $93 and $95 respectively while keeping positive ratings. The most recent move came Tuesday, when Piper Sandler raised its target from $86 to $90, though it held at Neutral — a reminder that not everyone is bullish despite the consensus drift higher. The mean target across the Street now sits at $92.25, a roughly 5% premium to the current price, which is consistent with a stock the market considers fairly valued rather than cheap. BofA, which cut its target from $103 to $99 back in mid-April during the broader market drawdown, remains the lone notable voice holding a Buy with a target above $99 — suggesting at least one major firm still sees meaningful room to run.
Short positioning does not tell a particularly charged story. Bears hold about 2.1% of the free float — a low absolute level — and that number has actually fallen around 3.7% on the week even as it crept up 10% over the past month. The borrow market remains essentially frictionless: cost to borrow is just 0.50%, barely above its recent range, and availability in the lending pool is extraordinarily loose at roughly 5,000% of short interest — meaning there are far more shares available to lend than are currently borrowed. That kind of availability profile rules out any squeeze dynamic. Options positioning corroborates the lack of tension: the put/call ratio at 1.26 is actually running a touch below its 20-day average of 1.29, and the z-score is mildly negative. Taken together, positioning looks relaxed rather than charged in either direction.
Valuation reflects a business that the market is comfortable paying a modest premium for. The trailing P/E has edged up about 0.8% over 30 days to 8.2x — cheap in absolute terms, though not unusual for a large-cap life insurer carrying investment-portfolio sensitivity. Price-to-book at 1.83x has drifted slightly lower on the week. The forward EPS growth angle is where the factor scores are most constructive: the 12-month forward EPS momentum score ranks in the 90th percentile, and 30-day and 90-day EPS momentum are both comfortably above 60. The short score at 35.6 has eased slightly from its 10-day high of 36.4, consistent with the modest short-interest trim. The ORTEX short score rank of 43 puts MET squarely in the middle of the universe — neither a name bears are pressing hard nor one they are abandoning.
Institutional ownership is deeply conventional. BlackRock, Vanguard, State Street, and T. Rowe Price collectively hold well over 20% of shares. T. Rowe added roughly 2.5 million shares as of its most recent filing — the largest directional move among top holders. The only notable insider activity in the past 90 days was a $1.7 million sale by the Chief Risk Officer in early June at $81.59, a routine transaction at a price well below the current level. The broad holder picture is stable.
Earnings history adds a note of caution worth tracking. The last three quarterly prints each produced a negative next-day reaction, ranging from -1.4% to -2.6%. The five-day outcomes were mixed, with some recovery after the initial dip. The next event is August 6. Between now and then, the question worth watching is whether the steady analyst target-raise cycle — which has now run through at least six firms over six weeks — continues to pull the consensus above $92, or whether the stock's approach toward those targets prompts a pause in positive revisions.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
